Avicanna Inc. (AVCN.TO)
| Previous Close | 0.3300 |
| Open | 0.3350 |
| Bid | 0.3400 x N/A |
| Ask | 0.3450 x N/A |
| Day's Range | 0.3150 - 0.3450 |
| 52 Week Range | 0.2000 - 0.6000 |
| Volume | |
| Avg. Volume | 135,212 |
| Market Cap | 40.754M |
| Beta (5Y Monthly) | 1.31 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.1000 |
| Earnings Date | Nov 12, 2024 - Nov 18, 2024 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
GlobeNewswireAvicanna Announces Medical Cannabis Real World Evidence Study through MyMedi.ca
1000 patient study on impact of medical cannabis on pain, sleep, anxiety, depression, and epilepsy Study to be led by Dr. Hance Clarke President of The Canadian Pain Society and the CCICTORONTO, Sept. 23, 2024 (GLOBE NEWSWIRE) -- Avicanna Inc. (“Avicanna” or the “Company) (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN) a biopharmaceutical company focused on the development, manufacturing, and commercialization of plant-derived cannabinoid-based products is pleased to announce a large-scale medical cannabi
- Baystreet
Stocks in play: Avicanna Inc.
Announced it has cleared and fully repaid $1,445,000 that was owed under the Debentures of August 2, ...
GlobeNewswireAvicanna Announces Repayment of Debentures
TORONTO, Aug. 30, 2024 (GLOBE NEWSWIRE) -- Avicanna Inc. (“Avicanna” or the “Company”) (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN), a commercial stage, international biopharmaceutical company focused on the development advancement, and commercialization of evidence-based, cannabinoid-based products, is pleased to announce it has cleared and fully repaid $1,445,000 that was owed under the Debentures of August 2 2023. About Avicanna Inc. Avicanna is a commercial-stage international biopharmaceutical com
